Dr. Fotios Asimakopoulos, MD

Dr. Asimakopoulos practices at Rush University Medical Center in Chicago, Illinois, part of Rush System for Health.

Dr. Asimakopoulos' NPI, 1518134923, was assigned on May 14, 2008. Dr. Asimakopoulos holds California license A115772.

Dr. Asimakopoulos' primary practice is Rush University Medical Center, at 1653 West Congress Parkway, Chicago, IL 60612 in Cook County. The practice phone is (312) 942-5000.

Dr. Asimakopoulos' primary practice is Rush University Medical Center in Chicago, Illinois, part of Rush System for Health. The medical group on file is Rush University Internists. Dmand AI also links Dr. Asimakopoulos to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Asimakopoulos practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Asimakopoulos' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Asimakopoulos' licenses on file in 2 states: California and Wisconsin.

CMS data shows 828 Medicare services from Dr. Asimakopoulos across 5 procedure codes in 2024, for 86 Medicare patients. Medicare paid $50,287 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 86 Medicare patients who saw Dr. Asimakopoulos in 2024. The largest group is 65 to 74, with 40 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 23% are also on Medicaid. Their average risk score is 3.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Asimakopoulos' median patient age at 71, with 48% women.

In 2024, Dr. Asimakopoulos wrote 223 Medicare Part D claims for 21 patients. 69% of them were for generic drugs. CMS names the drug for 149 of them, across 6 drugs with 11 or more claims each, at $719,980 in total drug cost. In 2023, CMS named 125 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Asimakopoulos for performance year 2024, reported as part of a group. Dr. Asimakopoulos accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 4 general payments to Dr. Asimakopoulos from 4 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 54% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $112.